Effect of recombinantly-derived bovine somatotropin on reproductive performance of dairy cattle

Factors affecting folliculogenesis in ruminants

This review addresses the reasons for the lack of progress in the control of superovulation and highlights the importance of understanding the mechanisms underlying follicular development. The present inability to provide large numbers of viable embryos from selected females still restricts genetic improvement, whilst variability in ovarian response to hormones limit the present capacity for increasing reproductive efficiency.

Females are born with a large store of eggs which rapidly declines as puberty approaches. If these oocytes are normal then there is scope for increasing the reproductive potential of selected females. Oocytes must reach a certain size before they can complete all stages of development and the final changes that occur late in follicular development. It is likely that oocytes that do not produce specific factors at precise stages of development will not be viable. Hence, it is important to characterize oocyte secreted factors since there are potential indicators of oocyte quality.

The mechanisms that determine ovulation rate have still not been fully elucidated. Indeed follicular atresia, the process whereby follicles regress, is still not known. A better understanding of these processes should prove pivotal for the synchronization of follicular growth, for more precise oestrous synchronization and improved superovulatory response.

Nutrition can influence a whole range of reproductive parameters however, the pathways through which nutrition acts have not been fully elucidated. Metabolic hormones, particularly insulin and IGFs, appear to interact with gonadotrophins at the level of the gonads. Certainly gonadotropins provide the primary drive for the growth of follicles in the later stages of development and both insulin and IGF-1, possibly IGF-2, synergize with gonadotrophins to stimulate cell proliferation and hormone production. More research is required to determine the effects of other growth factors and their interaction with gonadotropins.

There is evidence, particularly from studies with rodents, that steroids can also modulate follicular growth and development, although information is very limited for ruminants. There may be a rôle for oestrogens in synchronizing follicular waves, to aid in oestrous synchronization regimes and for removing the dominant follicle to achieve improved superovulatory responses. However more information is required to determine whether these are feasible approaches.

Heritability for litter size is higher in sheep than in cattle. Exogenous gonadotropins are a commercially ineffective means of inducing twinning in sheep and cattle. Although there are differences in circulating gonadotropin concentrations, the mechanism(s) responsible for the high ovulation appear to reside essentially within the ovaries. The locus of the Booroola gene, a major gene for ovulation rate, has been established but not specifically identified. However sheep possessing major genes do provide extremely valuable models for investigating the mechanisms controlling ovulation rate, including a direct contrast to mono-ovulatory species such as cattle.

In conclusion, the relationship between oocyte quality, in both healthy follicles and those follicles destined for atresia, must be resolved before the future potential for increasing embryo yield can be predicted. In addition, a greater understanding of the factors affecting folliculogenesis in ruminants should ensure that the full benefits ensuing from the precise control of ovarian function are achieved. The improved use of artificial insemination and embryo transfer that would ensue from a greater understanding of the processes of folliculo genesis, coupled with the new technologies of genome and linkage mapping, should ensure a more rapid rate of genetic gain.

Meta-analysis of the effects of sometribove zinc suspension on the production and health of lactating dairy cows

OBJECTIVE

To provide an updated evaluation of the efficacy and safety of sometribove zinc suspension (rbST-Zn), a form of recombinant bovine somatotropin, in lactating dairy cows.

DESIGN

Meta-analysis.

SAMPLE

26 studies published in peer-reviewed journals or reviewed by a regulatory agency.

PROCEDURES

To be included, a study had to involve the use of the rbST-Zn formulation available to US producers in accordance with the label instructions for treatment initiation (57 to 70 days postpartum), dose (500 mg, q 14 d), and route (SC).

RESULTS

For cows treated with rbST-Zn, mean milk, 3.5% fat-corrected milk, fat, and protein yields were increased by 4.00, 4.04, 0.144, and 0.137 kg/d (8.8, 8.89, 0.32, and 0.30 lb/d), respectively; however, the concentration of milk components did not change. Pregnancy proportion for the first 2 breeding cycles was increased by 5.4%, and pregnancy proportion for the duration of the trial was reduced by 5.5% for rbST-Zn-treated cows, compared with proportions for untreated cows. Mean body condition score (1 to 5 scale) was reduced by 0.06 points during the period of rbST-Zn use for treated cows. Administration of rbST-Zn had no effect on milk somatic cell count, the number of days to pregnancy, or inseminations per pregnancy; rates of fetal loss, twins, cystic ovaries, clinical lameness, lameness lesions, or traumatic lesions of the integumentary system; and odds of clinical mastitis or culling.

CONCLUSIONS AND CLINICAL RELEVANCE

Results indicated that rbST-Zn administration to dairy cows effectively increases milk production with no adverse effects on cow health and well-being.

Growth hormone regulation of follicular growth

The somatotropic axis – consisting of growth hormone (GH), the insulin-like growth factors 1 and 2 (IGF1 and IGF2), GH binding protein (GHBP), IGF binding proteins (IGFBPs) 1 to 6, and the cell-surface receptors for GH and the IGFs – has major effects on growth, lactation and reproduction. The primary target tissues for GH are involved in growth and metabolism. The functionality of the somatotropic axis depends in part on the expression of liver GH receptor (GHR), which determines the amount of IGF1 released from the liver in response to GH. The IGF1 acts as a pleiotropic growth factor and also serves as the endocrine negative feedback signal controlling pituitary GH secretion. Growth hormone and IGF1 undergo dynamic changes throughout the life cycle, particularly when animals are either growing, early post partum or lactating. Cells within the reproductive tract can respond directly to GH but to a lesser degree than the primary target tissues. The major impact that GH has on reproduction, therefore, may be secondary to its systemic effects on metabolism (including insulin sensitivity) or secondary to the capacity for GH to control IGF1 secretion. Insulin-like growth factor 1 and IGFBP are also synthesised within the ovary and this local synthesis is a component of the collective IGF1 action on the follicle. Future studies of GH should focus on its direct effects on the follicle as well as its indirect effects mediated by shifts in nutrient metabolism, insulin sensitivity, IGF1 and IGFBP.

Efeito da somatotropina bovina recombinante (rBST) sobre o desempenho produtivo e reprodutivo de vacas da raça Holandesa

Avaliaram-se os efeitos da aplicação de rBST sobre o desempenho produtivo e reprodutivo de vacas da raça Holandesa no início da lactação. Foram avaliadas 41 vacas, dos 60 aos 150 dias de lactação, distribuídas em um delineamento inteiramente ao acaso, em três tratamentos: 1- sem aplicação de rBST (controle); 2- aplicação de rBST 60 dias após o parto (rBST-60); 3- aplicação de rBST 100 dias após o parto (rBST-100). A aplicação de rBST aumentou a produção de leite e a produção de leite corrigida a 4% de gordura em 14,0 e 13,2%, respectivamente, quando administrada aos 60 dias pós-parto. Não se observou efeito da aplicação de rBST sobre a porcentagem e a produção de gordura do leite nem sobre o período de serviço, número de serviços por concepção e taxa de gestação aos 150 dias de lactação. O uso do rBST também não afetou o ganho de peso dos animais durante o período avaliado. A aplicação de rBST aos 60 dias de lactação proporcionou maiores pico de produção e persistência da lactação, sem, no entanto, influenciar o desempenho reprodutivo. A aplicação de rBST aos 100 dias de lactação não aumentou a produção de leite e o desempenho reprodutivo das vacas.

Effects of whole cottonseed diet and recombinant bovine somatotropin on ovarian follicles in lactating dairy cows

The effects of whole cottonseed (WCS) in the diet and the administration of bovine somatotropin (bST) on ovarian follicular dynamics and plasma progesterone (P4) concentrations were examined in cows during a period of synchronized follicular growth. Lactating Holstein cows (n = 28) were randomly assigned to treatments in a 2 x 2 factorial arrangement. Diets consisted of WCS (15% of dry matter) or no WCS, and bST at a dose of 0 or 208 mg/14 d. Dietary treatments began within 24 h of calving and bST treatments began within 7 d postpartum. Cows received GnRH at 65 +/- 3 d postpartum (d 0), PGF2alpha, (d 7), a second dose of GnRH (d 9), and were inseminated 16 h later (d 10). Ovarian changes were monitored daily by ultrasonography from d 0 to 9. On d 9,93% of cows had a preovulatory follicle and 86% ovulated. For Class 2 (6 to 9 mm) follicles, a diet x bST interaction was detected, with bST stimulating Class 2 follicles in cows fed WCS, but not in cows on the control diet. Neither diet nor bST affected numbers of Class 1 (2 to 5 mm) or Class 3 (> or = 10 mm) follicles or sizes of the subordinate and dominant follicles. During the luteal phase of the cycle, lactating cows fed WCS tended to have elevated concentrations of plasma P4, whereas bST was without effect. Plasma concentrations of high-density lipoprotein cholesterol were increased in cows fed WCS. Number and diameter of corpora lutea did not differ among treatments.

Influence of metabolic hormones and nutrition on ovarian follicle development in cattle: practical implications

Nutrition has long been known to have a profound influence on reproductive performance of female cattle, but the underlying mechanism remains poorly understood. Whilst early investigations focused on the modulation of nutrition on hypothalamic-pituitary axis, more recent studies have tested the hypothesis that metabolic hormones as nutritional signals exert a direct effect at the ovarian level. In cattle, treatment with recombinant bovine somatotrophin (rGH) significantly increases the population of small ovarian follicles. This is associated with increases in circulating concentrations of insulin and insulin-like growth factor-I (IGF-I). Subsequent studies, both in vitro and in vivo, have highlighted the importance of IGF-I and/or insulin acting in synergy with FSH and LH. More recently, we demonstrated that feeding heifers with 200% maintenance requirements for a short period significantly increases circulating insulin concentrations and population of small ovarian follicles. Based on these findings, our recent work has aimed at addressing some practical problems in cattle production. Firstly, we showed that both rGH pretreatment and increased dietary intake significantly enhance the response to standard superovulatory regimes. Secondly, we have demonstrated that feeding a diet to increase circulating insulin concentrations during the early lactation can advance the first ovulation postpartum and increase conception rate to the first service in dairy cows. In summary, nutrition influences ovarian follicle development in cattle possibly through changes in metabolic hormones. These interactions can be manipulated to improve reproductive performance.

Timing of onset of somatotropin supplementation on reproductive performance in dairy cows

The objective of this field trial was to determine whether delaying the start of recombinant bovine somatotropin (rbST) supplementation from 9 to 10 wk postpartum to 17 to 18 wk postpartum would improve reproductive performance in lactating dairy cows. Cows from nine herds (n = 798 cows; 766 Holsteins, 32 Jerseys) were assigned at random to receive rbST supplementation at 14-d intervals beginning during wk 9 to 10 (n = 399) or wk 17 to 18 (n = 399) after calving. Effects of herd, season of calving, parity, and onset of rbST supplementation (9 to 10 wk vs. 17 to 18 wk) on days to first service and days open were determined. In primiparous but not multiparous cows, there tended to be fewer days to first service and fewer days open when onset of rbST supplementation was delayed. Percentages of cows pregnant at 150, 200, and 250 d postpartum were also examined. Time of onset of rbST did not affect percentages of multiparous cows pregnant at 150, 200, and 250 d postpartum. However, there appeared to be a slight tendency for percentages of pregnant primiparous cows to be greater at 200 and 250 d postpartum for those receiving rbST supplementation beginning at 17 to 18 wk compared to those receiving rbST starting at 9 to 10 wk. In conclusion, delaying the start of rbST supplementation to wk 17 to 18 postpartum had no beneficial effect on reproductive performance of multiparous cows but tended to improve some measures of reproductive performance in primiparous cows.

Reproductive loss in high-producing dairy cattle: where will it end?

The dairy industry in the United States has changed dramatically in the last decade. Milk production per cow has increased steadily because of a combination of improved management, better nutrition, and intense genetic selection. Dairy farms are larger, and nearly 30% of the dairy cows in the United States are on farms with 500 or more cows. The shift toward more productive cows and larger herds is associated with a decrease in reproductive efficiency. Cows with the greatest milk production have the highest incidence of infertility, but epidemiological studies suggest that, in addition to milk production, other factors are probably decreasing reproductive efficiency in our dairy herds. The reproductive physiology of dairy cows has changed over the past 50 yr, and physiological adaptations to high milk production may explain part of the reproductive decline. Critical areas for new research include control of the estrous cycle, metabolic effects of lactation on reproduction, mechanisms linking disease to reproduction, and early embryonic mortality. Solving reproductive loss in dairy cows will not be easy because only a small number of research groups study reproduction in postpartum dairy cows. Therefore, the present research base will need to be expanded. For this to occur, research funding must be increased above its current level and a renewed emphasis must be placed on solving the emerging crisis of infertility in dairy cows.

Effects of sustained release bovine somatotropin (sometribove) on animal health in commercial dairy herds

The health of dairy cows given bovine somatotropin (bST) for one lactation was evaluated in 28 commercial herds located in four regions of the United States. At least six herds were in a region and at least one herd/region contained fewer than 60 cows. Cows (n = 1213) were assigned randomly to control or bST groups and were treated beginning in wk 9 to 10 of lactation and every 14 d until dry-off or d 400 of lactation. Management was according to site practices. Cows were observed for health-related signs by farm personnel daily and by the herd veterinarian biweekly. Average 305-d test-day milk yields were 932 kg greater for bST-treated cows. Pregnancy rates, days open, twinning, cystic ovaries, or abortions were unaffected by treatments. Supplementation of cows with bST had no effect on total mastitis cases, total days of mastitis, duration of mastitis, or the odds ratio of a cow to develop mastitis. Cows supplemented with bST used more medications for health events other than mastitis. This usage was associated primarily with treatments for disorders of the foot and hock. Supplemented cows had a slight increase in foot disorders. There was no effect of supplementation with bST on culling from the herd or removal from study. Overall, the results confirm that label directions for bST are adequate for safe use under field conditions. All clinical signs observed in this study occur normally in dairy herds and were managed in cows supplemented with bST.

Reproductive performance of Holstein cows receiving somatotropin

Some dairy producers resist using bovine somatotropin (bST) beginning at 9 wk postpartum because of the concern that fertility is compromised. We conducted a trial with a total of 205 Holstein cows, 100 multiparous and 105 primiparous, to evaluate reproductive performance in two high producing herds in Arizona and southern California. Rolling herd averages for both herds for milk production exceeded 10,700 kg/yr. Data were collected for cows calving December 1996 through August 1997. The voluntary waiting period was 60 d postcalving, with cows randomly assigned to receive bST or no treatment (controls). In the 180-d interval after calving, 65.4% (68/104) of the control cows were diagnosed pregnant. With bST-treated cows, 48.5% (49/101) were pregnant in that same interval. A chi-square value from a linear model indicated that pregnancy outcome differed significantly between treatment groups. With a similar method of analysis, first-service conception rate was not significantly different between treatment groups. An extended voluntary wait and breeding interval is recommended for cows receiving bST, similar to suggestions from other published reports.

Regulation of ovarian follicular growth by somatotropin and insulin-like growth factors in cattle

Somatotropin (ST), insulin-like growth factor (IGF)-I, and IGF-II affect animal growth and lactation as well as animal reproduction. Understanding the effects of ST and the IGF on reproduction is important because ST and IGF-I undergo dynamic changes prior to the postpartum breeding period. In addition, administration of recombinant bovine somatotropin (rbST) to lactating cows is a common practice that increases blood concentrations of ST and IGF-I during the breeding period. In vivo, administration of rbST caused greater ovarian follicular development. The effects of rbST may represent direct actions of ST because ST receptors are found within granulosa cells as well as oocytes. Alternatively, the actions of ST may be indirectly mediated by increased IGF-I and (or) nutrient partitioning that occurs after rbST. Both IGF-I and IGF-II are synthesized within the ovary. Ovarian IGF are, therefore, a composite of IGF from both endocrine (liver) and autocrine and paracrine (ovary) sources. The IGF stimulate ovarian function by acting synergistically with gonadotropins to promote growth and steroidogenesis of ovarian cells. Actions of IGF-I and -II are restrained by a series of IGF binding proteins (IGFBP) that either originate from the blood or are synthesized locally within the follicle. Degradation and differential synthesis of IGFBP are important mechanisms regulating IGFBP amounts. The relative amounts of IGFBP may ultimately determine ovarian IGF action. Future studies of ST and IGFs should focus on the hormones, receptors, and binding proteins as well as the metabolic requirements for normal ovarian function in dairy cattle.

Effect of long-term infusion with recombinant growth hormone-releasing factor and recombinant bovine somatotropin on development and function of dominant follicles and corpora lutea in Holstein cows

The objective of this study was to evaluate the effects of recombinant bovine growth hormone-releasing factor (rGRF) or recombinant bovine somatotropin (rbST) on growth and function of the first-wave dominant follicle and corpus luteum. Primiparous Holstein cows (117 d postpartum) were infused with 12 mg/d of rGRF (n = 10) or 29 mg/d of rbST (n = 10) for 63 d, and non-infused cows (n = 10) were controls. At slaughter on d 5 of an estrous cycle, blood and ovaries were collected and data from cows with a corpus luteum were analyzed (control, n = 8; rGRF, n = 5; rbST, n = 6). Treatment with rGRF or rbST increased somatotropin (ST) and IGF-I in serum similarly compared with controls. In contrast, rbST-treated cows had higher concentrations of ST in follicular fluid (FF) compared with rGRF-treated and control cows. In addition, rbST, but not rGRF, increased the number and decreased the size of estrogen-active follicles (EA; estradiol > progesterone concentrations in FF), increased the abundance of IGF binding proteins-2, -3, and -4 in FF from EA follicles, and increased the number but decreased the size of corpora lutea and decreased concentration of progesterone in serum compared with controls. Based on these results, we concluded that long-term infusion of rbST alters growth and function of the first-wave dominant follicle and the corpus luteum in cattle.

Recombinant bovine somatotropin: association with reproductive performance in dairy cows

A clinical trial was performed to determine the effect of bST on reproductive performance in dairy cows on 4 Michigan dairy farms when bST was used according to labeled directions. Holstein cows (n = 555) at 4 Michigan dairy farms were randomly assigned to receive bovine somatotropin (bST) or to serve as untreated controls. Bovine somatotropin (500 mg, s.c.) was administered every 14 d beginning at 63 to 69 d of lactation and continuing until approximately 21 d prior to the end of lactation or until the producer removed the animal from the herd. A total of 229 (42.57%) animals consisting of 112 (48.91%) controls and 117 (51.09%) bST-treated cows were not diagnosed pregnant and were considered as having reproductive failure by 150 d of lactation and 92 (17.10%) of the animals consisting of 45 (48.91%) controls and 47 (51.09%) bST-treated cows had reproductive failure at the end of their lactation. No significant difference in the incidence of reproductive failure existed between the study treatment groups during either time frame. Cows with cystic ovarian disease had more instances of reproductive failure at 150 d of lactation than cows without this disease. Cows with dystocia, twin births, metritis, displaced abomasum and cystic ovarian disease had more instances of reproductive failure by the end of lactation than cows without these diseases. The bST-treated cows developed more nonspecific off feed conditions during the study lactation and had more twin births at the calving following bST administration compared to control cows. No differences were found between the study treatment groups in calculations of reproductive parameters. Logistic regression analysis found no significant effect of bST on reproductive failure; the odds ratios for the bST treatment effect on reproductive failure at 150 d of lactation and reproductive failure at the end of lactation were 0.95 (95% CI 0.67 to 1.36) and 0.95 (95% CI 0.59 to 1.54), respectively. Overall, bST was not found to have a significant impact on reproductive performance in the herds studied.

Pregnancy outcomes in two commercial dairy herds following hormonal scheduling programs

There are a number of options for hormonal management of post partum dairy cows; however, only a few studies have made direct comparisons of these programs in commercial herd settings. We compared reproductive management programs of 2 commercial dairy herds to evaluate the efficacy of prostaglandin-based treatment regimens on reproductive outcomes. Cows in Herd A were left untreated and served as the negative controls. Cows in Herd B were given PGF2alpha every 14 d until first insemination beginning 45 d post partum and served as the positive controls. Treatment 1 (Ovsynch), initiated randomly during the estrous cycle, consisted of sequential injections of GnRH, PGF2alpha, GnRH again and insemination 16 to 20 h later. Treatment 2 consisted of an Ovsynch protocol, as described above, which was begun 7 d post estrus (Ovsynch + 7). In Herd A, the number of days from parturition to conception (days open) for controls, for Ovsynch and for Ovsynch + 7 were 126, 112 and 102, respectively. In Herd B, respective days open were 102, 100 and 93 for controls, Ovsynch and Ovsynch + 7. Hormonal intervention reduced the number of days open in both herds.

Plasma GH, IGF-I, and conception rate in cattle treated with low doses of recombinant bovine GH

Blood and uterine concentrations of GH and insulin-like growth factor (IGF)-I are correlated with improved fertility in cattle. We tested incremental doses of a 14-d sustained release recombinant bovine GH (rbGH) to increase blood GH and IGF-I (Experiments 1 and 2). Conception rate after administration of an optimized rbGH dose was also tested (Experiment 3). In Experiment 1, lactating Holstein cows (n = 18) were randomly assigned to receive 0 (n = 5), 100 (n = 5), 200 (n = 5), or 500 (n = 3) mg sc rbGH. Increasing the doses of rbGH was associated with increased serum concentrations of GH and IGF-I. The 100- and 200-mg doses caused an IGF-I release that was below and above, respectively, the perceived optimum response. Therefore, Experiment 2 was designed to test a rbGH dose (167 mg), which was intermediate to the doses tested in Experiment 1. Lactating and nonlactating postpartum beef cows were treated with 0 (n = 9) or 167 (n = 9) mg rbGH at insemination. Plasma concentrations of GH and IGF-I were greater in rbGH-treated cows than in controls. Lactating cows had initial IGF-I concentrations that were lower than nonlactating cows. The 167-mg dose of rbGH increased plasma IGF-I concentrations in lactating cows to the levels of those of nonlactating cows. In Experiment 3, cows and heifers were administered either 0 or 167 mg rbGH at insemination. The conception rate for rbGH-treated and control cows was 54.4 and 49.5% (n = 617), and 46.0 and 46.3% for heifers (n = 1123), respectively. Herd (P<0.01) and parity (P<0.01) affected conception rate, but conception rates for rbGH and control cattle were similar. In summary, low doses of rbGH increased blood GH and restored blood IGF-I concentrations in lactating cows to those of nonlactating cows, but the conception rate in cows and heifers was not affected by administration of 14-d sustained-release rbGH at insemination.

Follicular function in lactating dairy cows treated with sustained-release bovine somatotropin

The objective of this study was to determine the long-term, short-term, and residual effects of bovine somatotropin (bST) on ovarian function. Twenty-six Holstein cows were assigned to one of four groups and given either bST (500 mg) or saline for seven injection cycles (14 d between injections). Groups were 1) seven injection cycles of saline (control), 2) seven injection cycles of bST, 3) three injection cycles of bST followed by four injection cycles of saline, and 4) three injection cycles of saline followed by four injection cycles of bST. Beginning in the middle of the fourth injection cycle, an estrous cycle was synchronized for study. Serum concentrations of bST and insulin-like growth factor I were lowest during saline injections and increased after bST injections. Growth of the first wave dominant follicle was similar; however, start of the second follicular wave was approximately 48 h earlier in those cows treated with bST (groups 2, 3, and 4). Cows treated with somatotropin had a similar pattern of follicular growth, but tended to have more class 1 (3 to 5 mm) follicles and had more class 2 (6 to 9 mm) follicles than did the control cows. Peak concentrations of serum FSH were lower and occurred earlier for the cows treated with bST. There were no differences in the long-term or short-term effects of bST on ovarian function. Furthermore, cows that were switched from bST to saline (group 3) showed a residual effect of bST for up to 3 wk.

Interaction among bovine somatotropin, insulin, and gonadotropins on steroid production by bovine granulosa and thecal cells

The objective of the present study was to determine the interactions among bST, insulin, and gonadotropins on steroid production by granulosa and thecal cells from bovine follicles. Basal production of estradiol by granulosa cells from small (1 to 5 mm) and large (> or = 8 mm) follicles (expressed as picograms of estradiol per 10(5) cells per 24 h) was not affected by 50 or 300 ng/ml of bST, but 300 ng/ml of bST inhibited estradiol production that was induced by FSH plus insulin in cells from small and large follicles. Progesterone production and proliferation by granulosa cells from large follicles were not affected by 3 to 100 ng/ml of bST. In cultures of thecal cells that exhibited a > 3-fold increase in androstenedione production induced by LH, 3 to 30 ng/ml of bST further increased androstenedione production by 29 to 42%, but cell proliferation and progesterone production were unaffected by bST. In cultures of thecal cells that exhibited a < 2-fold increase in androstenedione production induced by LH, 3 to 30 ng/ml of bST inhibited androstenedione production by 32 to 33% and inhibited cell proliferation by 9 to 13%, but progesterone was unaffected by bST. In summary, only pharmacologic doses of bST inhibited estradiol production by granulosa cells, but physiologic doses of bST altered androstenedione production by thecal cells, which indicated that bST might not have an important role in granulosa cell function but might play a role in thecal cell function in cattle.

Production performance of dairy cattle administered recombinantly derived bovine somatotropin (USAN, Somavubove) daily: a dose range study

Herds (n = 9) were used on which cattle (n = 598) received 0, 4.3, 8.6, 12.9 or 17.2 mg of recombinant bovine somatotropin (rbST; USAN, Somavubove) daily from about 75 d postpartum until lactation end. Minimum effective dose to increase (3.5% fat corrected milk) FCM of cows (multiparous) compared with controls is 2.0 mg rbST/d and maximum is 16.6 mg/d. Minimum effective dose to increase FCM of heifers (primiparous) is 5.0 mg rbST/d while the maximum is 16.7 mg/d. Dosing of 4.3 to 13.2 mg rbST/d enhances efficiency of FCM production in cows. Milk fat, protein, calcium and phosphorus were not effected by rbST except for instances of transient changes. Lactose was greatest in heifers given 12.9 mg rbST/d. Days of lost milk, incidents of mastitis, and somatic cell counts were not affected by rbST. Cows given 12.9 or 17.2 mg of rbST had reduced pregnancy and conception rates, whereas heifers did not. Total services, first service conception rate, services per conception, days open and days to first AI (artificial insemination) were not affected by rbST. Days between AI were greater in cows given 17.2 mg rbST/d. Restoration of body weight and condition occurred at slower rates in rbST-dosed cows. Heifers given 8.6 or 12.9 mg rbST/d gained more weight than controls. Net energy and protein balance was reduced (less so in heifers) near start of rbST but recovered as intakes increased. Cattle given rbST produce more milk than controls and should be managed accordingly.

Extended function of the corpus luteum and earlier development of the second follicular wave in heifers treated with bovine somatotropin

Effects of recombinant bovine somatotropin (bST) on growth of the corpus luteum (CL) and development of ovarian follicles were tested. Starting at estrus (Day=0), the following treatments were administered: control (saline injected Days 0 to 19, n=5); bST[0-9] (25 mg bST injected Days 0 to 9, saline injected Days 10 to 19, n=5); bST[10-19] (saline injected Days 0 to 9, 25 mg bST injected Days 10 to 19, n=5); and bST[0-19] (25 mg bST injected Days 0 to 19, n=6). Blood was collected daily for progesterone analysis, and ultrasound examinations were performed daily for measurement of follicles and CL. Compared with the heifers treated with saline, those treated with bST had larger CL and more progesterone during the early (</= Day 10) and late (Days 15 to 21) phases of the estrous cycle. At mid-cycle (Days 10 to 15), luteal tissue area and progesterone levels were similar for bST- and saline-treated heifers. Ovarian follicular growth was similar for bST- and saline-treated heifers during the first follicular wave. However, during recruitment for the second follicular wave (Days 10 to 14), second largest follicles emerged sooner (P<0.001), the number of Class-3 (>/=10 mm) follicles was greater (P<0.01) and largest follicles were smaller (P<0.001) in bST than in saline-treated heifers. Estrous cycle length and ovulation rate were similar for each group. In conclusion, bST increased initial development of the CL and extended its function. Furthermore, the second follicular wave was earlier with bST.

Pregnancy incidence in high producing dairy cows treated with recombinant bovine somatotropin

Reproductive performance in cows exposed for two lactations to recombinant bST was measured using unconditional logistic regression. Intramuscular administration of 17.2, 51.6, and 86 mg of recombinant bST/d per cow started at d 70 postpartum and ended at dry-off or 305 d postpartum. Performance was measured as the cumulative incidence of cows becoming pregnant by 305 d post-partum. Within each parity group, cows treated with bST had higher total milk yield. During the first study lactation, the log odds of a cow becoming pregnant decreased linearly as dose increased, following adjustment for serum cholesterol, blood urea N, average daily milk yield, peak milk yield, net energy balance, and body condition score. However, differences in pregnancy incidence between treated and untreated cows were statistically significant only at the higher dose categories, the 51.6 and 86.0 mg of recombinant bST per cow. During the second study lactation, pregnancy rates were similar to those in the first lactation; rates reduced as recombinant bST dose increased. The singular exception was for cows exposed to recombinant bST during the previous lactation but not during the second. In the latter group, previously treated cows had higher pregnancy incidence than did the controls.

Effects of recombinant bovine somatotropin (sometribove) on ovarian function in lactating and nonlactating dairy cows

Metabolic and ovarian responses of lactating and nonlactating cows to recombinant bST (sometribove) were measured. Eighteen lactating cows (60 to 100 d postpartum) and 6 nonlactating cows (> 400 d postpartum) were injected daily with bST or saline during one of two periods. Concentrations of hormones and metabolites were measured in plasma, and ultrasonography was used to quantify ovarian follicular growth. Concentrations of glucose, insulin, IGF-I, progesterone, and estradiol in plasma were greater in nonlactating cows than in lactating cows. Lactating cows had fewer class 2 (6- to 9-mm) and class 3 (10- to 15-mm) follicles and more class 4 (> 15-mm) follicles than nonlactating cows. Bovine somatotropin increased the numbers of follicles in lactating cows so that the numbers of class 2 and of class 3 follicles were equivalent to those for non-lactating cows. Sizes of the largest follicles were similar for bST-and saline-treated cows. The second largest ovarian follicles, however, were larger in bST-treated cows. Ovarian follicular dynamics were altered by bST and lactation. Bovine somatotropin increased the numbers of follicles (6 to 15 mm) in lactating cows and size of second largest ovarian follicles in both lactating and nonlactating cows. Lactating cows developed dominant follicles that were larger and less estrogenic than those of nonlactating cows.

Ovarian follicular populations in lactating dairy cows treated with recombinant bovine somatotropin (sometribove) or saline and fed diets differing in fat content and energy

Interactions of dietary energy and fat with recombinant bST (sometribove) injections were tested for their effects on ovarian function. Lactating dairy cows were fed one of three diets differing in energy concentration (NEL) and percentage of DM of calcium salts of long-chain fatty acids: diet 1, 1.68 Mcal/kg and 0%; diet 2, 1.68 Mcal/kg and 2.2%; and diet 3, 1.78 Mcal/kg and 2.2%. Cows were injected daily with bST or saline during one of two 19-d interestrous periods (crossover design) in which ovarian follicles were measured by ultrasonography. The bST-treated cows produced more FCM and were in lower energy balance than saline-treated cows. Before d 12 (first follicular wave, estrus = d 0), bST-treated cows had more ovarian follicles in classes 1 (3 to 5 mm; cows on diet 3) or 2 (6 to 9 mm; cows on diets 1 and 2) than saline-treated cows. After d 12 (preovulatory follicular wave), numbers of follicles in different size classes were similar for bST-treated and saline-treated cows, but cows fed diet 2 had larger preovulatory follicles. Lower dietary energy and bST treatment were both associated with larger subordinate follicles. Ovarian follicles less than 10 mm were stimulated by bST, and calcium salts of long-chain fatty acids increased diameters of preovulatory follicles.

Effects of treatment of dairy cows with recombinant bovine somatotropin over three or four lactations

Jersey, Dutch Red and White, and Friesian cows were subcutaneously injected with 640 mg of recombinant bST at 28-d intervals from 87 to 115 d after calving through four successive lactations. A TMR (6.72 MJ of NEL) and 168 g of CP/kg of DM) was fed for ad libitum consumption. The bST effects per day were 3.3 kg for milk yield, 189 g for fat yield, 109 g for protein yield, 157 g for lactose yield, 4 MJ of NEL for feed intake, and -4 kg for body weight. Responses in blood parameters measured 7 d after injection were -.007 mmol/L for glucose, -1.3 mg of N/100 ml for urea, 221 mumol/L for 3-hydroxybutyrate, 59 mumol/L for NEFA, 65 ng/L for insulin, 2.8 micrograms/L for thyroxine, and 26.7 micrograms/L for somatotropin. Somatic cell count in milk was 75,000 cells/ml higher in treated cows. Concentrations of NEFA, Ca, Mg, and phosphorus were unaffected. Repeatability of the maximum response in milk yield after bST treatment was low: .2 within and .5 between lactations. Cows treated in the previous lactation had slightly more retained placentas, and birth weight of their calves was 2 kg less. No differences were observed between treated and control cows in disease incidence. Six treated cows were culled in third and fourth lactations. No indications for tissue damage, inflammation, or stress after bST injections were detected.

Effects of a prolonged-release formulation of sometribove (n-methionyl bovine somatotropin) on Jersey cows

Milk production, feed efficiency, health, and reproduction were evaluated in 46 Jersey cows that received either 500 mg of sometribove (n-methionyl bST) in a prolonged-release formulation or an equivalent volume of excipient bi-weekly beginning at 60 +/- 3 DIM. Cows were fed a TMR for ad libitum intake and were milked twice daily. Treatment with sometribove increased 3.5% FCM production 5.3 kg/d (31.4%) over controls. Milk composition was not changed, except that milk P content averaged 51 ppm higher in bST-treated cows. Net energy intake was 4.8 Mcal/d (22.9%) higher in the bST-treated cows than in the controls. General health of all cows was good throughout the study, but the cows treated with bST had more cases of mastitis than did the control cows. The bST treatment produced localized reactions at the site of injection in some cows, but these reactions did not affect milk production. Sometribove treatment had no effect on reproductive performance; 85% of the treated and 100% of the control cows calved successfully. Treatment with bST for a full lactation did not affect performance during the initial 60 d of the subsequent lactation.